Zobrazeno 1 - 10
of 89
pro vyhledávání: '"502"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vasiliki Metaxa-Mariatou, Paul Zarogoulidis, Eirini Papadopoulou, Barbounis Vassilios, George Pentheroudakis, Nikolaos Tsoulos, Stylianos Kakolyris, Jenny Bourkoula, George Nasioulas, Anna Koumarianou, Katerina Skapeti, Georgios N. Tsaousis, Ioannis Boukovinas, Chrisoula Efstathiadou, Ilias Athanasiadis, P. Papakotoulas, Theofanis Floros, Georgia Tounta
Publikováno v:
Journal of Clinical Oncology. 35:e23193-e23193
e23193 Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with broad spectrum of targeted therapies already available or in clinical trials. Thus, molecular characterization of the tumor using the Next G
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Clinical Oncology. 34:99-99
99 Background: Understanding about young adults with advanced cancer in palliative care was still insufficient. The purpose of this study was to identify the differences in symptom distress between young (20-39 years) and older (≥ 40 years) adults
Publikováno v:
Journal of Clinical Oncology. 41:198-198
198 Background: The aim of this study was to explore the prognostic value of the lung immune prognostic index (LIPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Me
Autor:
Guillermo de Velasco, Iciar García-Carbonero, Emilio Esteban-Gonzalez, Alvaro Pinto, David Lorente, Alfonso Gomez De Liano Lista, Esther Martínez Ortega, Laura Jimenez Colomo, Javier Puente, Iria Gonzalez, Ovidio Fernandez-Calvo, Georgia Anguera
Publikováno v:
Journal of Clinical Oncology. 41:502-502
502 Background: Urothelial carcinoma (UC) commonly affects patients (pts) who are ineligible for full doses of cisplatin-based chemotherapy (CT) due to bad performance status, advanced age, or renal impairment. The combination of split-dose cisplatin
Autor:
Jinsil Seong, Jina Kim, Jason Chia-Hsien Cheng, Taek-Keun Nam, Jin Hee Kim, Wen-Yen Huang, Hiroshi Aikata, Myungsoo Kim, Jinbo Yue, Victor Ho-Fun Lee, Zhaochong Zeng
Publikováno v:
Journal of Clinical Oncology. 41:565-565
565 Background: While systemic treatment is the mainstay for advanced hepatocellular carcinoma (HCC), numerous studies have highlighted the added value of local treatment. This study aimed to investigate the clinical efficacy of liver-directed combin
Autor:
Léamarie Meloche-Dumas, Frédéric Mercier, Tori Barabash, Calvin Law, Simron Singh, Sten Myrehaug, Wing Chan, Julie Hallet
Publikováno v:
Journal of Clinical Oncology. 41:647-647
647 Background: While there have been major advances in the care of neuroendocrine tumors (NETs), there is still no widely adopted therapeutic sequencing in metastatic NETs. The roles and benefits of locoregional treatments need reassessment, in orde
Publikováno v:
Journal of Clinical Oncology. 41:502-502
502 Background: Cholangiocarcinoma (CCA) is an epithelial malignancy of the intrahepatic or extrahepatic biliary tree, primarily driven by chronic inflammation and fibrosis. Given fibrosis has shown to correlate with malignancy and the aminotransfera
Autor:
Charles H. McDonnell, Andrew G. Hudnut, Deepti Behl, Roger Ang, Barbara Spinelli, Debbie Jacobs, Ina Kim, Kristie Bobolis
Publikováno v:
Journal of Clinical Oncology. 40:e15037-e15037
e15037 Background: A blood-based multi-cancer early detection (MCED) test is available for use as a complement to single cancer screening modalities, though clinical experience is limited. PATHFINDER (NCT04241796; enrollment complete, n = 6662) is a